SALİH Çetiner

Prof. Dr. SALİH Çetiner


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
HDHakan Demirhindi
Hakan Demirhindi
BMBURAK METE
BURAK METE
FTFerdi Tanir
Ferdi Tanir
EKERTAN KARA
ERTAN KARA
FKFİLİZ KİBAR
FİLİZ KİBAR
SASukriye Ece Akti
Sukriye Ece Akti
This study aimed to evaluate the mixed and homogeneous application of the inactivated SARS-CoV-2 vaccine CoronaVac (CV) and the mRNA vaccine BNT162b2 (BNT). This prospective cohort study included 235 health care workers who had received two prime shots with CoronaVac. They were divided into three cohorts after the third month: Cohort-I (CV/CV); Cohort-II (CV/CV/CV); and Cohort-III (CV/CV/BNT). Anti-S-RBD-IgG and total anti-spike/anti-nucleocapsid-IgG antibody concentrations were examined in vaccinated health workers at the 1st, 3rd, and 6th months following the second dose of the vaccination. The mean age of 235 health care workers who participated in the project was 39.51 ± 10.39 (min-max: 22–64). At the end of the 6th month, no antibodies were detected in 16.7% of Cohort-I participants, and anti-S-RDB IgG levels showed a decrease of 60% compared to the levels of the 3rd month. The antibody concentrations of the 6th month were found to have increased by an average of 5.13 times compared to the 3rd-month levels in Cohort-II and 20.4 times in Cohort-III. The heterologous vaccination strategy “CoronaVac and BNT162b2 regimen” is able to induce a stronger humoral immune response and it will help remove inequalities in the developing world where CoronaVac was the initial prime.

26 June 2018 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
GTGokhan Tumgor
Gokhan Tumgor
MAMehmet Agin
Mehmet Agin
FDFigen Doran
Figen Doran
SÇSALİH Çetiner
SALİH Çetiner

5 March 2017 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
PDF file
SÇSALİH Çetiner
SALİH Çetiner
ADAlev Çetin Duran
Alev Çetin Duran
FKFİLİZ KİBAR
FİLİZ KİBAR
AYAkgün Yaman
Akgün Yaman

25 July 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
FTFerdi Tanir
Ferdi Tanir
BMBURAK METE
BURAK METE
HDHakan Demirhindi
Hakan Demirhindi
EKERTAN KARA
ERTAN KARA
ENErsin Nazlican
Ersin Nazlican
CKCeren Kanat
Ceren Kanat
This prospective cohort study aimed to evaluate the efficacy of COVID-19 vaccine schemes, homologous versus heterologous vaccine strategies, and vaccine-induced anti-S-RBD-IgG antibody response in preventing COVID-19 among 942 healthcare workers 1 year after vaccination with the inactivated and/or mRNA vaccines. All participants received the first two primary doses of vaccines, 13.6% of them lacked dose 3, 50.5% dose 4, and 90.3% dose 5. Antibody levels increased with the increase in number of vaccine doses and also in heterologous vaccine regimens. In both inactive, mRNA vaccines and mixed vaccination, infection rates were significantly higher in two-dose-receivers, but lower in four- or five-dose receivers and increasing the total number of vaccine doses resulted in more protection against infection: the three-dose regimen yielded 3.67 times more protection, the four-dose 8 times, and five-dose 27.77 times more protection from COVID-19 infection, compared to any two-dose vaccination regimens. Antibody levels at the end of the first year of four- or five-dose-receivers were significantly higher than two- or three-dose receivers. To conclude, an increased number of total vaccine doses and anti-S-RBD antibody levels increased the protection from COVID-19 infection. Therefore, four or more doses are recommended in 1 year for effective protection, especially in risk groups.

19 February 2024 in Tumor Discovery
Verified
Journal Article
Open access
PDF file
FOFesih OK
Fesih OK
MEMustafa Emre
Mustafa Emre
ABAtıl Bışgın
Atıl Bışgın
SJSamir Jafarguliyev
Samir Jafarguliyev
IBIbrahim Boga
Ibrahim Boga
SDSaban Doran
Saban Doran
The emission of radiofrequency electromagnetic radiation (RF-EMR) from mobile phones has been implicated in causing inflammatory changes in the testis. Nevertheless, the direct association of these changes with the development of testicular germ cell tumors (TGCT) remains unclear. Therefore, we purposed to investigate the effect of RF-EMR exposure on inflammatory changes in the testis, cytokine gene expression levels, and the incidence of TGCT. Twenty male Wistar albino rats were randomly assigned to either the study or control groups. The study group was exposed to RF-EMR at 900 MHz, 26 V/m, and a specific absorption rate (SAR) of 0.14 W/kg for 4 h/day over 8 weeks. Histopathological analysis, vitality analysis using Annexin V, and real-time polymerase chain reaction for the analysis of interleukin 1 (IL-1), IL-4, IL-10, tumor necrosis factor-alpha, and interferon-gamma (IFN-γ) cytokine gene expressions were performed on the testicular tissue. The median testis weight (163.0 g [133.0 – 183.0] vs. 179.0 g [134.0 – 195.0], P = 0.012) and volume (0.95 cm3 [0.800 – 1.400] vs. 1.100 cm3 [1.050 – 1.500], P = 0.031) of the study group were significantly lower compared to the control group. The seminiferous tubule damage (P < 0.001) and interstitial edema (P = 0.042) were significantly higher in the study group. The tunica albuginea thickness was significantly reduced in the study group (P < 0.001). The fold changes in the expression levels of IL-4 and IFN-γ increased significantly in the study group. Our findings indicate that RF-EMR exposure causes structural, histopathological, and inflammatory toxic effects on the testis. The observed elevation in gene expression levels of IL-4 and IFN-γ cytokines following RF-EMR exposure suggests their potential role as regulators of TGCT initiation, thereby offering a viable potential therapeutic target in combination with current treatments. Nonetheless, future well-designed studies are necessary to validate our findings.

2 March 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
HDHakan Demirhindi
Hakan Demirhindi
BMBURAK METE
BURAK METE
FTFerdi Tanir
Ferdi Tanir
EKERTAN KARA
ERTAN KARA
FKFİLİZ KİBAR
FİLİZ KİBAR
SASukriye Ece Akti
Sukriye Ece Akti
This study aimed to evaluate the mixed and homogeneous application of the inactivated SARS-CoV-2 vaccine CoronaVac (CV) and the mRNA vaccine BNT162b2 (BNT). This prospective cohort study included 235 health care workers, who had received two prime shots with CoronaVac. They were divided into three cohorts after the third month: Cohort-I (CV/CV); Cohort-II (CV/CV/CV) and Cohort-III (CV/CV/BNT). Anti-S-RBD-IgG and total an-ti-spike/anti-nucleocapsid-IgG antibody concentrations were examined in vaccinated health workers at the 1st, 3rd and 6th months following the second dose of the vaccination. The mean age of 235 health care workers who participated in the project was 39.51±10.39 (min-max: 22-64). At the end of the 6th month, no antibodies were detected in 16.7% of Cohort-I participants, and anti-S-RDB IgG levels showed a decrease of 60% compared to the levels of the 3rd month. The antibody concentrations of the 6th month were found to have increased by an average of 5.13 times compared to the 3rd-month levels in the Cohort-II and 20.4 times in Cohort-III. The heterologous vaccination strategy “CoronaVac and BNT162b2 regimen” is able to induce a stronger immunity and it will help remove inequalities in the developing world where CoronaVac was the initial prime.